COMMUNIQUÉS West-GlobeNewswire
-
Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
15/06/2026 -
Sanofi: Information concerning the total number of voting rights and shares – May 2026
15/06/2026 -
Boston Business Journal names Interra Health to 2026 Best Places to Work List
15/06/2026 -
Curaechoice Partners with Capitol Imaging Services to Deliver Greater Access to No-Cost Diagnostic Imaging for Program Members
15/06/2026 -
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
15/06/2026 -
Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED
15/06/2026 -
GENFIT : Résultats de l’Assemblée Générale Mixte du 15 juin 2026
15/06/2026 -
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mai 2026
15/06/2026 -
Major Shareholder Announcement
15/06/2026 -
Medicana Health Group Celebrates Two Major Recognitions in Capital Magazine’s CSR Research
15/06/2026 -
Applied Biologics Reports Statistically Significant Improvement in Wound Closure Outcomes in Updated Analyses of the CAMPX Randomized Controlled Trial Evaluating XWRAP®
15/06/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
15/06/2026 -
SafeSpace Global Appoints Michael Hrynuik as Chief Financial Officer
15/06/2026 -
KFSH Demonstrates How Specialized Hospitals Can Drive Health System Innovation at HLTH Europe 2026
15/06/2026 -
France Biotech to Showcase the Strength and Global Momentum of French HealthTech at BIO International Convention 2026 in San Diego
15/06/2026 -
BioSyent to Present at Planet MicroCap Las Vegas
15/06/2026 -
Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
15/06/2026 -
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
15/06/2026 -
Cardiawave Announces First Routine Treatments Performed with Valvosoft® Following CE Mark Approval and Accelerates Its Deployment
15/06/2026
Pages